{"license":"https://creativecommons.org/licenses/by/4.0/","dataset":"event-entities","count":1,"summary":{"policyEntityCount":21,"relationshipCount":31,"officialEventCount":14,"linkedEventCount":12,"unlinkedEventCount":2,"marketCount":7,"sourceCount":11,"agencyCount":4,"profileCrosswalkCount":6,"firstYear":2019,"latestYear":2026,"spanLabel":"2019-2026"},"guardrail":"A relationship means an official source names the organization in connection with the dated record. It does not by itself establish liability, market power, ownership, control, or that the organization participates in every market linked to that record.","crosswalkGuardrail":"Optional participant and operator crosswalks are observatory navigation aids based on matched public labels. They are not legal-entity, affiliate, beneficial-owner, or corporate-control determinations.","policyEntityFilters":{"policyEntity":"emisar-pharma-services-llc","policyEntityMatched":true,"entityId":"pent-emisar-pharma","slug":"emisar-pharma-services-llc","name":"Emisar Pharma Services LLC","role":null,"roleMatched":null},"rows":[{"id":"peel-emisar-complaint","eventId":"evt-pbm-insulin-complaint-2024","eventDate":"2024-09-20","eventTitle":"FTC files administrative complaint against the three largest PBMs","eventStage":"litigation","eventType":"complaint","agency":"Federal Trade Commission","docketNumber":"Docket No. 9437","entityId":"pent-emisar-pharma","entitySlug":"emisar-pharma-services-llc","entityName":"Emisar Pharma Services LLC","role":"respondent","roleLabel":"Respondent","evidenceSummary":"The FTC administrative complaint names affiliated GPO Emisar Pharma Services as a respondent.","markets":[{"id":"mkt-pbm","slug":"us-pharmacy-benefit-management","name":"U.S. pharmacy benefit management"}],"sourceId":"ftc-pbm-insulin-complaint-2024","sourceTitle":"FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices","sourcePublisher":"Federal Trade Commission","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices","sourceAccessDate":"2026-07-17","profileHref":null,"profileKind":null,"policyEntityProfileHref":"/enforcement/entities/emisar-pharma-services-llc","recordProfileHref":"/enforcement/records/pbm-insulin-complaint-2024","enforcementHref":"/enforcement?policyEntity=emisar-pharma-services-llc&enforcementEvent=evt-pbm-insulin-complaint-2024#enforcement-relationship-atlas","guardrail":"A relationship means an official source names the organization in connection with the dated record. It does not by itself establish liability, market power, ownership, control, or that the organization participates in every market linked to that record.","crosswalkGuardrail":"Optional participant and operator crosswalks are observatory navigation aids based on matched public labels. They are not legal-entity, affiliate, beneficial-owner, or corporate-control determinations.","sourceProfileHref":"/sources/ftc-pbm-insulin-complaint-2024"}]}